Clinuvel Pharmaceuticals Ltd Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Clinuvel Pharmaceuticals Ltd

CLVLY 8.750

0.0%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: caly who wrote (11)	1/30/2007 8:17:45 PM
From: caly	Read Replies (1) of 52

Clinuvel UK approval for Phase 3 trial 10:02, Wednesday, 31 January 2007 Sydney - Wednesday - Jan 31: (RWE Australian Business News) - Clinuvel Pharmaceuticals Limited (ASX:CUV) reports ethics approval has been granted by the UK's Central Office for Research Ethics Committees (COREC) to commence a Phase III clinical trial of Clinuvel's photo-protective drug, CUV1647, in Polymorphous Light Eruption (PLE). This approval follows the company's recent announcement regarding the approval of the Phase III PLE trial by the Medicines and Healthcare products Regulatory Agency (MHRA). The trial, to be conducted at Hope Hospital in Manchester, UK, is the first site to be granted the necessary regulatory and Medical Ethics Committees (MEC) approval. Patients are currently being recruited. Clinuvel’s next step is to obtain approval from the relevant MECs in the remaining trial sites across Europe.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next